MICROPOS MEDICAL AB
NNGM:MPOS0.84
SEK
0.00
(0.00%)
MICROPOS MEDICAL AB
NGM:MPOS
(Nordic Growth Market)
Recent
price
0.84
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Micropos Medical AB is a Sweden-based medical technology company that develops, manufactures, and commercializes precision solutions for real-time organ tracking and motion management in radiation oncology. Founded in 2003 and headquartered in Gothenburg, Sweden, the company operates in the medtech and radiation therapy sectors, focusing on technologies that enhance treatment accuracy, facilitate hypofractionated radiation protocols, and reduce radiation exposure to healthy surrounding tissue during the treatment of prostate cancer and other soft-tissue malignancies. The company’s primary product offerings include the Raypilot System, an electromagnetic 4D real-time localization and tracking platform equipped with a treatment couch sensor plate, signal processing unit, and positioning software designed for integration with medical linear accelerators; Raypilot HypoCath, a single-use catheter embedded with an electromagnetic transmitter that delivers continuous real-time positional data without requiring surgical implantation of gold fiducial markers; Raypilot Transmitters, specialized positioning beacons engineered for precise anatomical motion tracking throughout radiotherapy delivery; and Raypilot Software Suites, proprietary software providing motion-detection algorithms, beam-hold gating interfaces, and data integration with oncology information systems and treatment platforms such as Varian and Elekta. Micropos Medical AB markets and distributes its products to hospitals, comprehensive cancer centers, and academic radiotherapy departments across Europe and selected international territories through direct sales channels and specialized distributor networks. In recent operational developments, the company has broadened its commercial footprint through new distribution and agency agreements across key European markets; advanced its regulatory certifications under the European Union Medical Device Regulation framework for its Raypilot HypoCath catheter and sensor systems; completed equity financing rounds through rights issues to support international commercialization and production scale-up; expanded multicenter clinical validation studies evaluating real-time tracking during extreme hypofractionation regimens; and enhanced technical interoperability collaborations to integrate its real-time motion management technology with modern image-guided radiation therapy and surface-guided radiation therapy workflows.